Homepage>Company>Media>Pharma News>2018>Eureka Therapeutics Closes $60 Million in Series D Financing to Advance Proprietary ARTEMIS™ T Cell Receptor Platform for Safer T Cell Therapies
Eureka Therapeutics Closes $60 Million in Series D Financing to Advance Proprietary ARTEMIS™ T Cell Receptor Platform for Safer T Cell Therapies